Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858477 | 1.00 | SYK (0.52) | SYKKCNH2AURKBKDR | |
| SCHEMBL14241494 | 0.78 | SYK (0.79) | SYKKCNH2AURKBKDR | |
| SCHEMBL14241441 | 0.78 | SYK (0.79) | SYKKCNH2AURKBKDR | |
| SCHEMBL19495664 | 0.78 | SYK (0.79) | SYKKCNH2AURKBKDR | |
| SCHEMBL1550002 | 0.77 | SYK (0.53) | SYKKCNH2AURKB | |
| SCHEMBL12235411 | 0.77 | SYK (0.53) | SYKKCNH2AURKB | |
| SCHEMBL12385958 | 0.75 | METAP1 (0.47) | SYKKCNH2KDR | |
| SCHEMBL1856348 | 0.75 | SYK (0.73) | SYK | |
| SCHEMBL1851854 | 0.75 | SYK (0.73) | SYK | |
| SCHEMBL17403921 | 0.75 | SYK (0.52) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2324022-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010015520-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015520-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | NR4A1, NR4A3, NR0B1 | SYK 2086/4885KCNH2 1386/4885AURKB 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.